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Objectives: The purpose of this study was to determine the prognostic value of B-type natriuretic peptide (BNP) in patients with chronic severe 
mitral regurgitation (MR), undergoing mitral valve surgery.
Background: Currently, surgical timing of chronic severe MR is mainly based on symptomatic status and echocardiographic parameters such as 
left ventricular ejection fraction and end-systolic dimension. But the timing of surgery is still controversial. The prognostic value of BNP for surgical 
outcome in patients with chronic MR has not been studied.
Methods: 117 consecutive chronic MR patients undergoing surgery were prospectively enrolled. Patients were excluded from the study if they had 
acute MR or acutely decompensated heart failure, significant renal, pulmonary, coronary or other significant valvular heart disease. The plasma BNP 
level assay and echocardiographic studies were done before surgery. Study endpoint was a composite of death, readmission with heart failure, newly 
development of atrial fibrillation, or stroke during follow-up.
Results: The median duration of follow-up was 3.8 years and the study endpoint was reached in 21 (17.9%) patients. Receiver-operator 
characteristic curve analysis yielded an optimal cutoff point of 125 pg/ml for BNP which was able to discriminate patients with poor prognosis. 
Kaplan-Meier survival analysis and log-rank test showed that patients with BNP ≥125 pg/ml had worse clinical outcome after surgery for chronic 
severe MR. For study endpoint, BNP and NYHA functional class were independent predictors by multivariate analysis (odds ratio: 3.236 [95% 
confidence interval: 1.081 - 9.687], p = 0.036 for BNP ≥125 pg/ml; odds ratio: 3.010 [95% confidence interval: 1.023 - 8.860], p = 0.045 for 
NYHA functional class ≥III).
Conclusions: Among patients with chronic severe MR undergoing mitral valve surgery, BNP independently predicts poor clinical outcome. BNP level 
might be useful in determining optimal timing for surgery in patients with chronic MR.
